Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Angiotech Pharmaceuticals, a specialty pharmaceutical and medical device company, has reported that its corporate partner, Boston Scientific, has received approval from the FDA to market its second-generation Taxus Liberte paclitaxel-eluting coronary stent system.
Subscribe to our email newsletter
Boston Scientific plans to launch the Taxus Liberte stent in early November 2008 in the US, following completion of the introduction of its Taxus Express(2) Atom paclitaxel-eluting coronary stent system, which was approved by the FDA in September 2008.
Jim Tobin, president and CEO of Boston Scientific, said: “We believe the approval of Taxus Liberte is a clear indication that we have made significant progress toward resolving the issues related to the corporate warning letter.”
William Hunter, president and CEO of Angiotech, said: “The US approvals of the Taxus Liberte and Atom represent the second and third generation of paclitaxel-eluting coronary stents to be launched by Boston Scientific – at a time when many others are still using first-generation technology. Over this time, the paclitaxel platform has shown tremendous efficacy and longevity in the treatment of millions of patients with life-threatening heart disease. Boston Scientific continues to make progress advancing the Taxus program and we believe it will be a mainstay of therapy for many years to come.”